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Abstract  
Background: Morphologic abnormalities of the pituitary gland volume (PV) have 
been reported in schizophrenia, but at what point in time they occur remains unclear. 
This study determines PV across different stages of emerging psychotic disorders 
compared to healthy controls. 
Methods: We compared PV of 36 individuals with an at-risk mental state (ARMS) for 
psychosis, 23 patients with a first episode psychosis (FEP) and 20 healthy controls 
(HC). Transition to psychosis was monitored using the BPRS transition criteria 
according to Yung et al. (Yung, A.R. et al., 1998. Prediction of psychosis. A step 
towards indicated prevention of schizophrenia. Br. J. Psychiatry Suppl. 172 
(33), 14-20). Applying these transition criteria, 16 of the 36 ARMS individuals made 
the transition to psychosis (ARMS-T) and 20 did not (ARMS-NT). We traced PV 
manually on 1 mm slices of magnetic resonance images in three dimensions 
(coronal, sagittal and axial) blind to group status. We used univariate analysis of 
covariance (ANCOVA) with PV as dependent variable, group and sex as between-
subject factors and whole brain volume as covariate.  
Results: PV increased from HC to ARMS-NT to ARMS-T/FEP. ANCOVA revealed a 
significant effect of group (F3,78 = 3.0; p = .036) and a sex x group interaction (F3,78 = 
6.5; p = .001). Over all groups, women had considerably larger PV than men (F1,78 = 
9.8; p = .003).  
Conclusions: Our findings provide further evidence that PV is increased with 
emerging psychotic disorders, and suggest that this is due to a stress-associated 
activation of the pituitary gland. 
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1. Introduction 
Magnetic resonance imaging (MRI) studies of the pituitary gland volume (PV) 
indicate that the pituitary is a dynamic organ which seems to change its 
volume in response to different influencing factors, such as age or stress. It is 
larger in females than in males and increases for example in puberty, 
pregnancy or with the administration of exogenous estrogens (for review, see 
Pariante (2008)).  
Also in psychotic disorders PV seems to be increased. As recent research 
has shown, the pituitary seems already to be increased during the prodromal 
phase of psychosis (Garner et al., 2005). Pariante et al. (2005; 2004) also 
found increased PV in neuroleptic-free patients with a first episode psychosis 
(FEP compared to healthy controls (HC). Following this enlargement, 
however, the pituitary seems to become smaller in established, treated 
schizophrenia (Pariante et al., 2004). Upadhyaya et al. (2007) found 
decreased PV in antipsychotic-naïve schizophrenia patients after an average 
duration of psychosis of two years. They and also Tournikioti et al. (2007) 
found an inverse relationship between duration of illness and PV.  
The pituitary gland produces different hormones which have been described 
to be abnormal in schizophrenic psychoses. Thus, it secretes 
adrenocorticotropic hormone (ACTH), which regulates the hypothalamic-
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pituitary-adrenal (HPA) axis, and HPA abnormalities have been described in 
psychoses (for review, see Pariante (2008)). Furthermore, it secretes the 
follicle stimulating hormone (FSH) and luteinizing hormone (LH) that regulate 
the hypothalamic-pituitary-gonadal (HPG) axis, which has been found to be 
suppressed in patients with schizophrenia (Riecher-Rössler et al., 1998; 
1994). It also produces prolactin which has been shown to be increased in 
many patients with schizophrenic psychoses, even in neuroleptic-free FEP 
patients (Kahn et al., 2008) and in at-risk mental state (ARMS) individuals 
(Rechsteiner et al., 2007; Aston et al., 2010). Thus, it could well be that 
schizophrenic psychoses are associated with an abnormal volume of the 
pituitary as a consequence of a dysfunction in these hormonal systems.  
We therefore examined PV changes in emerging psychosis and assessed the 
timing of the changes in an MRI study. We compared PV between HC, FEP 
patients, and ARMS individuals. We further compared PV between ARMS 
who made a transition to psychosis (ARMS-T) and ARMS individuals who did 
not (ARMS-NT). Based on previous neuroimaging studies of subjects with 
ARMS (see above; for review see Smieskova et al. (2009)), we expected PV 
to increase with the emergence of psychosis (HC < ARMS-NT < ARMS-T < 
FEP). To our knowledge this is the first study comparing these four groups. 
 
2. Materials and methods  
2.1. Study design 
This imaging study was embedded in a naturalistic, prospective study on the 
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prediction of transition to psychosis in individuals with ARMS, the Basel Early 
Detection of Psychosis (FePsy) study. A more detailed description of the 
overall study design can be found elsewhere (Riecher-Rössler et al., 2007). 
The  Ethics Committee of Basel, Switzerland (EKBB), approved all aspects of 
the study and written informed consent was obtained from each participant.   
 
2.2. Participants 
Recruitment started in February 2000. Subjects were recruited over a four-
year period from a service area covering 200 000 inhabitants in and around 
Basel, Switzerland. The last follow-up assessment was in May 2007. Eighty-
two subjects agreed to participate in the imaging arm of the FePsy study. Two 
HC with very large PV (904 mm3 and 913 mm3, more than three times out of 
standard deviation) were excluded to avoid the leverage effect of outliers in 
regression analyses and one of the ARMS-NT subjects had to be excluded 
due to an indefinable pituitary structure on MRI (prior to unblinding the group 
status). Therefore, a total of 79 participants (36 ARMS, 23 FEP and 20 HC) 
were included in the statistical analysis. The exclusion of three subjects from 
statistical analysis explains the slight differences in sample size to a recently 
published study comparing hippocampal volumes in the same sample 
(Buehlmann et al., 2009). 
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2.3. Screening procedure 
For screening purposes, we used the Basel Screening Instrument for 
Psychosis (BSIP) (Riecher-Rössler et al., 2008), a 46-item instrument based 
on variables which have shown to be risk factors for psychosis (Riecher-
Rössler et al., 2007; 2006). These include DSM-III-R – ‘prodromal’ symptoms, 
social decline, drug abuse, previous psychiatric disorders or genetic liability 
for psychosis, as well as the assessment of the severity of possible (pre-
)psychotic phenomena (“attenuated” psychotic symptoms). Experienced 
psychiatrists and psychologists who underwent regular training conducted all 
assessments. 
 
2.4. Inclusion criteria 
2.4.1. ARMS group 
The ARMS group was defined using the BSIP (Riecher-Rössler et al., 2008) 
in conjunction with the Personal Assessment And Crisis Evaluation (PACE) 
criteria (Phillips et al., 2002a; Yung et al., 1998) previously employed in 
similar MRI studies  (Borgwardt et al., 2007a; 2007b; Garner et al., 2005; 
Pantelis et al., 2003; Phillips et al., 2002b; Velakoulis et al., 2006). Inclusion 
thus required one or more of the following: a) “attenuated” psychotic 
symptoms, b) Brief Limited Intermittent Psychotic Symptoms (BLIPS), or c) a 
first or second degree relative with a psychotic disorder plus at least two 
indicators of a clinical change, such as a marked d
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occupational functioning. Symptom severity was rated on the Brief Psychotic 
Rating Scale (BPRS), extended version (Lukoff et al., 1986). Inclusion 
because of “attenuated” psychotic symptoms required BPRS scores of 2 or 3 
on the hallucination item, 3 or 4 on the unusual thought content and/or 
suspiciousness items for at least several times a week and persisting for more 
than 1 week. Inclusion because of BLIPS required BPRS scores of ≥4 on the 
hallucination item, or ≥5 on the unusual thought content, suspiciousness or 
conceptual disorganization items, with each symptom lasting less than 1 week 
before resolving spontaneously.    
 
2.4.2. FEP group 
The FEP group was defined applying the transition criteria according to Yung 
et al. (1998), see Table 1. At least one of the symptoms must occur at least 
several times a week and persist more than one week. 
Insert TABLE 1 approx. here. 
  
2.4.3. HC group 
The HC group was recruited from the same geographical area by local 
advertisements. An experienced psychiatrist excluded the presence of a 
current or past psychiatric disorder, head trauma, neurological illness, serious 
medical or surgical illness, substance dependency (except for cannabis and 
nicotine) and family history of a major psychiatric disorder.  
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2.5. Exclusion criteria 
Exclusion criteria were: age below 18 years, insufficient knowledge of 
German, IQ <70, previous episode of schizophrenic psychosis treated with 
major tranquilizers for more than 3 weeks (lifetime), psychosis due to organic 
brain disease or substance dependency, or psychotic symptoms within a 
clearly diagnosed depression or borderline personality disorder. The latter 
differs to the Melbourne ultra-high risk ascertainment strategy that does not 
exclude subjects with a major depression with psychotic features, or 
borderline personality disorder with psychotic symptoms. We decided to 
exclude these subjects if the primary diagnosis of major depression or 
borderline personality disorder was present prior to the ARMS to focus on a 
narrower at-risk sample for schizophrenia. 
When it was not suitable to perform an MRI (e.g. pacemaker, metal in the 
body), subjects were excluded from the imaging part of the FePsy study. 
 
2.6. Clinical follow-up and transition to psychosis 
All subjects were offered supportive counseling and clinical management. 
During the first year of follow-up, ARMS individuals were assessed monthly. 
During the second and third year, all individuals were assessed 3-monthly and 
thereafter once a year until the end of May 2007 or until transition to frank 
psychosis. Transition to psychosis was monitored using the BPRS transition 
criteria according to Yung et al. (1998). Applying these transition criteria, 16 of 
the 36 ARMS individuals made the transition to psychosis (ARMS-T) and 20 
did not (ARMS-NT). The diagnosis was determined by a diagnostic interview 
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using ICD-10 research criteria at the time of transition, corroborated by a 
subsequent assessment at least one year post transition using OPCRIT 
(Operational Criteria OPCRIT checklist for psychotic and affective illness) 
(McGuffin et al., 1991). 
 
2.7. Structural MRI 
2.7.1. Image acquisition 
All participants were scanned using a Siemens (Erlangen, Germany) 
Magnetom Vision 1.5 T scanner at the University Hospital Basel. Head 
movement was minimized by foam padding and velcro straps across the 
forehead and chin. A three-dimensional volumetric spoiled gradient recalled 
echo sequence generated 176 contiguous, 1-mm thick sagittal slices. Imaging 
parameters were: time-to-echo, 4 msec; time-to-repetition, 9.7 msec; flip 
angle, 12; matrix size, 200 x 256; field of view, 25.6 x 25.6 cm matrix; voxel 
dimensions, 1.28 x 1 x 1 mm. 
Original DICOM data were then converted to Analyze 7.5 format in axial 
direction coded to ensure blindness of the investigator and patients’ 
confidentiality and finally imported into the image-analysis software AMIRA 
(Kappos et al., 2006). 
2.7.2. Manual segmentation of pituitary gland volume 
The pituitary glands (Figure 1) were manually traced in the interactive public 
domain software program AMIRA by the same trained a
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investigator (JB) using a method described by Sassi et al. (2001). The 
pituitary stalk was excluded, but the posterior pituitary was included. We 
traced around the borders of the pituitary in the same way as Pariante et al. 
(2004), Garner et al. (2009; 2005), MacMaster et al. (2007a), and Nicolo et al. 
(2010): the diaphragma sellae superiorly, the sphenoid sinus inferiorly, and 
the cavernosus sinus laterally. First, the pituitary was traced in all coronal 
slices where it could be visualized. In addition to the method of Sassi et al. 
(2001), the tracing was then corrected in sagittal and axial dimensions to be 
finally controlled on the coronal slices again. Partial volume effects were taken 
into account. The software calculates the traced ROI volume in mm3 by 
summing the number of voxels of each traced slice. Intra-rater reliability in a 
subset of 10 scans measured twice within two weeks was .98. The whole 
brain volume was measured to correct for differences in head size as 
previously described (Borgwardt et al., 2007a; 2007b; Haller et al., 2009). 
 
Insert FIGURE 1 approx. here 
 
2.7.3. Image processing for whole brain volumes 
The fully automated software SIENAX (structural image evaluation, using 
normalization, of atrophy in a single-time-point estimation) was used for 
estimation of whole brain volumes from a single image, normalized for skull 
size (Smith et al., 2007). This method has been described elsewhere in detail 
(http://www.fmrib.ox.ac.uk/fsl/siena/index.html).  
Briefly, the software first strips non-brain tissue, and then uses the brain and 
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skull images to estimate the scaling between the subject's image and 
standard space. It then runs tissue segmentation to estimate the volume of 
brain tissue, and multiplies this by the estimated scaling factor, to reduce 
head-size-related variability between subjects (Smith et al., 2002). 
 
2.8. Statistical analysis  
We performed all analyses using the Statistical Package for the Social 
Sciences (SPSS) version 15. Clinical and demographic differences between 
groups were examined by one-way analysis of variance (ANOVA) or chi-
square test (Monte Carlo exact significance). Differences in PV were 
compared using univariate analysis of covariance (ANCOVA) with PV as 
dependent variable, group (HC, ARMS-NT, ARMS-T, FEP) and sex as 
between-subject factors and whole brain volume as covariate.  
The relationships between PV and demographic or clinical variables were 
examined with Pearson’s correlation coefficient r. Statistical significance was 
defined as P <.05 (two-tailed). 
 
3. Results 
3.1. Sample characteristics 
The main demographic data and baseline clinical features of HC, ARMS-NT, 
ARMS-T and FEP are presented in Table 2. There were no significant 
differences between the groups in sex, age or whole brain volume. FEP 
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participants were scanned within 1-3 days of first contact. More than half of 
the FEP patients (14/23) were antipsychotic-naïve. The remaining nine 
participants were prescribed atypical antipsychotic medications (six of them 
for less than one month; three participants received risperidone, six 
olanzapine). 
Thirty-two out of thirty-six ARMS individuals never received antipsychotic 
medication. Four participants had received low doses of atypical antipsychotic 
medication for behavioral control by the referring psychiatrist or general 
practitioner (three participants olanzapine, one risperidone) prior to study 
inclusion, all four for less than one month. Reanalyzing the data after 
excluding the nine FEP and four ARMS participants who were exposed to 
antipsychotic medication as outlined above did not change the overall results. 
Despite the markedly reduced sample size, the group x sex effect remained 
highly significant (F3,57=4.750, p=.005), and the group effect became a trend 
(F3,57=2.361, p=.081). All reported analyses therefore included the whole data 
set of 79 participants (independent of medication status). Furthermore, results 
did not change after adding age as covariate. 
 
Insert TABLE 2 approx. here 
 
3.2. Pituitary gland volumes (PV) 
Correlational analyses of PV did not reveal a significant association between 
PV and whole brain volume (Pearson’s ρ = -.059, p = .607) or age (Pearson’s 
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ρ = -.024, p = .833) but did with sex (ANOVA: F1,78 = 9.8; p = 0.003). As 
expected, over all groups women had significantly larger PV than men. 
Regression analysis for sex-adjusted mean revealed PV increases from HC to 
ARMS-NT to ARMS-T/FEP (see Table 3). The ANCOVA model with PV as 
dependent variable, group and sex as factors, and whole brain volume as 
covariate was significant for group effect (F3,78 = 3.0; p = .036). Additionally, 
there was a significant sex x group interaction (ANCOVA: F3,78 = 6.5; p = 
.001). Female sex in the ARMS-T group mainly drove this effect (see Figure 
2). These findings remained the same after adding age as covariate.  
Insert TABLE 3 approx. here 
Insert FIGURE 2 approx. here 
 
4. Discussion 
This ROI-based MRI study compared PV of individuals with ARMS according 
to transition status (ARMS-T, ARMS-NT) with FEP patients and HC. Pituitary 
volume increased from HC to ARMS-NT to ARMS-T/FEP (see Table 3). Our 
finding of a slightly larger PV in ARMS-T and FEP suggests that the gradual 
emergence of the first psychotic episode is associated with an activation of 
the pituitary function.  
 
4.1. Are pituitary volume abnormalities associated with activation of 
stress hormones during emerging psychosis? 
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Our findings support previous work of Garner et al. (2005) and Pariante et al. 
(2008; 2004) suggesting that PV is increased already prior to the first 
psychotic episode in ARMS participants who will convert to psychosis and that 
PV enlargement is most pronounced with the first psychotic breakdown.  
We further suggest that the increased pituitary volume in these patients might 
be due to over-activation of the stress response systems of the pituitary, 
associated with the development of psychosis. Thus, both ACTH and prolactin 
are so-called 'stress hormones', i.e. their secretion in the pituitary can be 
activated by psychological distress (for review, see (Pariante, 2008; Riecher-
Rössler et al., 1998)).  
4.1.1. ACTH as a stress hormone 
Several lines of evidence point towards an altered HPA axis function in 
emerging psychotic disorders (Phillips et al., 2006). Increased levels of 
circulating cortisol and ACTH were found in drug-naïve first episode patients 
with schizophrenia (Ryan et al., 2004; Sachar, 1970). Furthermore, non-
suppression of cortisol on the dexamethasone suppression test was found in 
some patients with schizophrenia, also in drug-naïve first episode cases 
(Coryell and Tsuang, 1992; Herz et al., 1985; Lammers et al., 1995; Tandon 
et al., 1991; Tandon et al., 1989). A small pilot study of patients with an at-risk 
mental state for psychosis also suggests that the HPA axis may already be 
dysfunctional prior to the first psychotic episode, particularly in ARMS subjects 
with depressive symptoms (Thompson et al., 2007). Regarding the time 
course of the volume changes, it was suggested that increased PV in ARMS-
T and in FEP subjects may be the consequence of an acute (repetitive) HPA 
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axis activation, whereas in established schizophrenia repeated episodes of 
HPA axis hyperactivity may lead to suppression of the HPA axis and result in 
smaller PV (Berger et al., 2007; Pariante, 2008; Phillips et al., 2006). Recently 
Mondelli et al. (2008), based on their finding of enlarged PV even in 
unaffected relatives of patients with psychosis, have suggested that the 
enlargement could partly also be a preexisting abnormality due to a genetic 
susceptibility to overactivate the HPA axis.  
4.1.2. Prolactin as stress hormone 
Also prolactin secretion of the pituitary is activated by stress and could partly 
explain the pituitary volume abnormalities: PV increase might be due to 
activation of prolactin-producing lactotroph cells (MacMaster et al., 2007a; 
2007b; Pariante et al., 2005; Riecher-Rössler et al., 1998). 
Prolactin levels are increased by many antipsychotics (for review, see 
(Riecher-Rössler et al., 2009). And Mondelli et al. (2008) as well as 
MacMaster et al. (2007a) have shown that first-episode and chronic patients 
with schizophrenia who were receiving prolactin-elevating antipsychotics had 
an increased pituitary volume compared with controls. Thus, PV increase 
could theoretically also be associated with antipsychotic-induced 
hyperprolactinaemia. However, the robustness of our findings after excluding 
the four ARMS and the nine FEP subjects receiving antipsychotic medication 
at the time of scanning indicate that the PV effects can also be related to the 
illness itself and are not always a medication effect.  
In this context it is interesting to note that prolactin in schizophrenia patients 
has shown to be increased also independent of antipsychotics (Rechsteiner et 
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al., 2007). And recently we have shown that prolactin is increased in many 
neuroleptic-free FEP patients (Kahn et al., 2008) and even in neuroleptic-
naïve ARMS patients (Aston et al., 2010), although overall results remain 
discussed controversially (for review, see Pariante (2008)).  
It is also unlikely, that PV differences in ARMS-T or FEP can be explained by 
antidepressant use, which is partly prescribed in this population, as long-term 
use of antidepressants hardly affects prolactin production (Molitch, 2005).  
4.2. Is pituitary volume increase associated with increasing LH and 
FSH? 
Also FSH and LH are produced in the pituitary. Theoretically it is also possible 
that the increase in PV is additionally due to an increased production of FSH 
and LH. This would be an indirect consequence of hyperprolactinaemia as the 
latter is known to suppress the HPG axis and the production of estrogens. 
Hypoestrogenism in a feedback-loop could then stimulate FSH and LH 
production.  
In this context it is interesting to note that a dysfunction of the hypothalamo-
pituitary-gonadal (HPG) axis with hypoestrogenism has been described in 
women with schizophrenia long before the introduction of antipsychotics (for 
review, see (Riecher-Rössler and Häfner, 1993; Riecher-Rössler et al., 
1998)).  
Interestingly, mainly the female ARMS-T group drove the overall group 
difference (see Figure 2). It could be speculated that this is due to a hormonal 
dysbalance especially in women – either the women being more stress-
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sensitive or stronger reacting with pituitary dysfunction. Also, in the above-
mentioned study (Rechsteiner et al., 2007; Aston et al., 2010) mainly ARMS 
women showed hyperprolactinaemia independent of antipsychotics . 
As expected from literature (for review see (MacMaster et al., 2007b; 
Pariante, 2008)), women in our study had a significantly larger PV than men. 
This gender difference has been described in healthy volunteers, but also in 
patients with psychosis or ARMS subjects (Garner et al., 2005; Pariante, 
2008; Upadhyaya et al., 2007). MacMaster et al. (2007b; 2006a; 2006b) also 
showed sex differences of PV in pediatric obsessive-compulsive disorder and 
in major depressive disorder, suggesting that this is not specific for certain 
psychiatric disorders.  
4.3. Limitations of our study and future perspectives 
In contrast to Garner et al. (Garner et al., 2005) we did not find a statistically 
significant difference in PV between ARMS-T and ARMS-NT (although there 
was a numerical difference). These differences may not only be explained by 
limited statistical power due to small sample sizes but also by different 
ascertainment strategies. Thus, the FePsy-Clinic at the University Psychiatric 
Outpatient Department of the Psychiatric University Clinics Basel only 
includes subjects from 18 years onwards, whereas ORYGEN Youth Health 
includes subjects from 15 to 25 years of age (prior to 2002 up to 29 years of 
age). ORYGEN also includes subjects with a primary diagnosis of major 
depression or borderline personality disorder (BPD) presenting with psychotic-
like or psychotic symptoms, whereas the FePsy study explicitly excludes such 
subjects.  
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Due to the modest sample size in the subgroup analysis we cannot exclude a 
statistical type II error and the possibility of missing small group differences. 
Furthermore, small differences in anatomic ROI definition and different MR 
acquisition parameters (e.g. different slice thickness) across studies may 
explain some of the discrepancies between studies.  
Furthermore, PV and morphology seem to be influenced by many additional 
factors, such as the variability in neuroendocrine activity, e.g. during the 
hormonal cycle (Dinc et al., 1998) that we were unable to control for, and 
additional environmental factors (Kumar and Pariante, 2004; Phillips et al., 
2006).  
To finally address the question of the timing of PV changes across the stages 
of emerging psychotic disorders, further prospective longitudinal 
neuroimaging studies from ARMS onwards would be useful. Such studies 
should also include testing of pituitary function by measuring circulating 
cortisol, ACTH and prolactin levels, or the dexamethasone suppression test 
(DST) in combination with PV measurements to better understand the role of 
the pituitary in emerging psychotic disorders. Furthermore, the specificity of 
the findings for schizophrenic psychoses should be further investigated as 
hyperactivity of the pituitary function, i.e. HPA axis or prolactin secretion, and 
consecutive PV abnormalities can also occur in other conditions associated 
with psychological stress (e.g. Sassi et al. (2001), McMaster et al. (2006a), 
Jovev et al. (2008)). 
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5. Conclusions 
In conclusion, our findings seem to indicate that volumetric alterations of the 
pituitary gland emerge during the prodromal and peri-onset phase of 
psychotic disorders and may reflect a hyperactivation of hormonal functions of 
the pituitary gland, particularly in women. Our findings especially encourage 
further investigation of the role of the HPA/HPG-axis as well as prolactin in 
emerging psychotic disorders as all of them have already been shown to be 
dysfunctional in psychosis. Of special interest are ACTH and prolactin as both 
are so-called 'stress hormones' and thus might well be involved in the 
pathogenesis of the disorder. 
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Figure Legends 
 
 
Figure 1.  The pituitary gland in a sagittal (left), transversal (centre) and 
coronal (right) magnet resonance image  
 
 Traced pituitary is located between the white lines. 
 
 
Figure 2.  Pituitary gland volumes across groups 
 
 Boxplot with median, upper and lower quartiles and standard 
deviation separated for groups and sex. Men: HC n = 13, ARMS-
NT n = 10, ARMS-T n = 11, FE n = 17. Women: HC n = 7, ARMS-
NT n = 10, ARMS-T n = 5, FE n = 6 
